Triple receptor agonist
GIP + GLP-1 + glucagon balanced activity.
FOR RESEARCH PURPOSES ONLY — This compound is not FDA approved. All data presented is from peer-reviewed literature for educational reference.
Metabolic Peptide
GLP-3
- Retatrutide
- LY3437943
- GIP/GLP-1/Glucagon Tri-Agonist
A 39-residue triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors — used as a research compound in metabolic and incretin-signaling studies.
Strength
- Free shipment protection
- Free shipping on $250+
- Damage protection
- 256-bit SSL checkout
39-residue design
Stabilized backbone characterized in published research literature.
99%+ identity purity
HPLC + MS verified per batch. CoA included.
What Is GLP-3?
GLP-3 (LY3437943) is a 39-amino-acid synthetic peptide engineered for balanced agonism at the gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Characterized in preclinical and clinical research literature exploring integrated multi-receptor signaling.
Technical specifications
Type
Synthetic 39-residue triagonist peptide
Molecular weight
~4,900 g/mol
Appearance
White lyophilized powder
Identity purity
≥ 99% (HPLC + MS)
Peer-reviewed research
- N Engl J MedTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
- LancetRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
Frequently researched together
IMPORTANT RESEARCH NOTICE
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.